Dermatitis最新文献_第4页

Dupilumab for the Treatment of Severe Atopic Dermatitis in an Immunosuppressed Transplant Patient. 杜匹单抗治疗免疫抑制移植患者的严重特应性皮炎

IF 5.2 3区医学

Dermatitis Pub Date : 2024-01-01 Epub Date: 2023-08-10 DOI: 10.1089/derm.2023.0181

Afsoon Ghafari-Saravi, Teri M Greiling

引用次数: 0

Cinnamic Aldehyde Causing Chronic Oral Mucosal Ulcerations. 肉桂醛导致慢性口腔黏膜溃疡

IF 5.2 3区医学

Dermatitis Pub Date : 2024-01-01 Epub Date: 2023-05-23 DOI: 10.1089/derm.2023.0043

Jordan Phillipps, Jeremy G Light, David Sheinbein

引用次数: 0

Allergic Contact Stomatitis Caused by (Meth)acrylates in a Gingival Protection Product Used During Teeth Whitening. 牙齿美白过程中使用的牙龈保护产品中的（甲基）丙烯酸酯引起的过敏性接触口炎。

IF 5.2 3区医学

Dermatitis Pub Date : 2024-01-01 Epub Date: 2023-08-24 DOI: 10.1089/derm.2023.0180

Michitaro Hayakawa, Yuko Baba, Michiyoshi Kouno

引用次数: 0

Efficacy of Dupilumab in Children 6 Months to 11 Years Old With Atopic Dermatitis: A Retrospective Real-World Study in China. 杜匹单抗对 6 个月至 11 岁特应性皮炎患儿的疗效：中国的一项回顾性真实世界研究。

IF 5.2 3区医学

Dermatitis Pub Date : 2024-01-01 Epub Date: 2023-02-17 DOI: 10.1089/derm.2022.0069

Nali Yang, Yahui Ye, Junyi Shao, Hanwen Wu, Qiuyang Xu, Jilin Zhu, Jingjing Liu, Zhiming Li

{"title":"Efficacy of Dupilumab in Children 6 Months to 11 Years Old With Atopic Dermatitis: A Retrospective Real-World Study in China.","authors":"Nali Yang, Yahui Ye, Junyi Shao, Hanwen Wu, Qiuyang Xu, Jilin Zhu, Jingjing Liu, Zhiming Li","doi":"10.1089/derm.2022.0069","DOIUrl":"10.1089/derm.2022.0069","url":null,"abstract":"Background: Atopic dermatitis (AD) is a common skin disease that affects patients' quality of life, especially in the pediatric population. Dupilumab has shown good efficacy and safety in the treatment of AD in adolescents and adults, but the real data on younger children using dupilumab are scarce. Objectives: We investigated the doses, efficacy, and safety of dupilumab in children with moderate-to-severe AD aged ≥6 months to 11 years. Methods: This single-center retrospective cohort analysis included dupilumab-treated patients with severe AD under 12 years of age. Primary endpoints included the proportion of Validated Investigator Global Assessment (vIGA) 0/1 achieved and the percentage change from baseline in eczema area and severity index (EASI) and SCORing Atopic Dermatitis (SCORAD) at week 24 (W24). Secondary endpoints were mean change in pruritus numerical rating score (P-NRS) and body surface area (BSA) after W24 of treatment, description of adverse events, and Children's Dermatology Life Quality Index (CDLQI) improvement from baseline in endpoints. Results: Fifty-seven patients were included (mean age 7.2 ± 3.0 years). The primary endpoint (vIGA = 0/1) was achieved by 51 of 57 (89.5%) patients at W24. Significant improvements in EASI, SCORAD, P-NRS, and CDLQI scores were observed from baseline to W24 with dupilumab treatment and remained until W40. In different age groups, the endpoint vIGA achieved 0/1: 95.2% (20/21) of younger children and 88.9% (32/36) of older children. No serious adverse drug reactions were reported. Conclusions: This study aimed to describe the safety and efficacy of dupilumab in pediatric patients and examined differences of efficacy with various doses. The outcomes are comparable with those of existing clinical trials. Phase III Clinical Trial: NCT03346434.","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":null,"pages":null},"PeriodicalIF":5.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9091370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Retrospective Analysis of Risk Factors for Atopic Dermatitis Severity. 特应性皮炎严重程度风险因素的回顾性分析

IF 5.2 3区医学

Dermatitis Pub Date : 2024-01-01 Epub Date: 2023-04-26 DOI: 10.1089/derm.2023.0037

Min Luo, Huichun C Su, Jinger E Lin, Changhua H Zhu, Lihang H Lin, Yue Han

{"title":"A Retrospective Analysis of Risk Factors for Atopic Dermatitis Severity.","authors":"Min Luo, Huichun C Su, Jinger E Lin, Changhua H Zhu, Lihang H Lin, Yue Han","doi":"10.1089/derm.2023.0037","DOIUrl":"10.1089/derm.2023.0037","url":null,"abstract":"Background: Atopic dermatitis (AD) has the highest burden of any skin disease; however, the severity-associated factors remain unclear. Objective: To evaluate potential severity-associated factors of AD and to design and validate a severity prediction model to inform the management of AD patients. Methods: A cross-sectional study of 900 AD patients was conducted from December 2021 to October 2022 at our hospital. The primary outcome was disease severity, categorized as mild, moderate, or severe using the scoring atopic dermatitis index. Ordinal logistic regression and bootstrapped validation were used to derive and internally validate the model. Results: Increasing age, elevated eosinophil level, higher economic status, and urban residence were associated with severe AD. Breastfeeding, disinfectants and topical emollients use, and short duration of bathing were associated with mild AD. In the prediction model, predictors included age, eosinophil and economic status, residence, feeding, disinfectants and emollients use, and duration of bathing. Prediction models demonstrated good discrimination (bias-corrected concordance index [c-index] = 0.72) and good calibration. Conclusion: Risk factors for the severity of AD were identified that could aid the early prediction of AD progression. The predictive model included variables that are easily evaluated and could inform personalized prevention and therapy.","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":null,"pages":null},"PeriodicalIF":5.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9763594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Review of Dupilumab-Induced Adverse Events to Dermatologists and the Potential Pathogenesis in the Treatment of Atopic Dermatitis. 回顾杜匹单抗在治疗特应性皮炎过程中给皮肤科医生带来的不良反应以及潜在的发病机制。

IF 5.2 3区医学

Dermatitis Pub Date : 2024-01-01 Epub Date: 2023-05-19 DOI: 10.1089/derm.2022.0096

Jun-Hong Tsai, Tsen-Fang Tsai

{"title":"A Review of Dupilumab-Induced Adverse Events to Dermatologists and the Potential Pathogenesis in the Treatment of Atopic Dermatitis.","authors":"Jun-Hong Tsai, Tsen-Fang Tsai","doi":"10.1089/derm.2022.0096","DOIUrl":"10.1089/derm.2022.0096","url":null,"abstract":" Dupilumab, a monoclonal antibody targeting interleukin-4 antibody, is approved for use in many type 2 inflammatory diseases, including atopic dermatitis. It is generally well tolerated with no need of routine laboratory monitoring. However, several adverse events have been reported during real-world practice and in pivotal trials. We conducted a systematic literature research of the PubMed, Medline, and Embase databases to identify articles recording the clinical manifestation and potential pathogenesis of these adverse events with interests (AEIs) to dermatologists. In total, 547 cases from 134 studies have developed 39 AEIs 1 day to 2.5 years after dupilumab treatment. The most common AEIs are facial and neck dermatitis (299 cases), psoriasis (70 cases), arthralgia (56 cases), alopecia (21 cases), cutaneous T cell lymphoma (19 cases), severe ocular diseases (19 cases), and drug eruption (6 cases). Most of the AEIs recorded in this review resolved or improved after dupilumab discontinuation or the addition of another treatment, whereas 3 of the cases died of severe AEI. The potential pathogenesis included T help type 1 (Th1)/T help type 2 (Th2) imbalance, Th2/T help type 17 (Th17) imbalance, immune reconstitution, hypersensitivity reaction, transient hypereosinophilia related, and Th1 suppression. Clinicians should be alert of these AEIs for timely diagnosis and appropriate treatment.","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":null,"pages":null},"PeriodicalIF":5.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9844361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Which Clinical Measurement Tools for Atopic Dermatitis Severity Make the Most Sense in Clinical Practice? 哪些特应性皮炎严重程度临床测量工具在临床实践中最有意义？

IF 5.2 3区医学

Dermatitis Pub Date : 2024-01-01 Epub Date: 2023-04-11 DOI: 10.1089/derm.2022.0087

Shanthi Narla, Jonathan I Silverberg

{"title":"Which Clinical Measurement Tools for Atopic Dermatitis Severity Make the Most Sense in Clinical Practice?","authors":"Shanthi Narla, Jonathan I Silverberg","doi":"10.1089/derm.2022.0087","DOIUrl":"10.1089/derm.2022.0087","url":null,"abstract":" Assessment of atopic dermatitis (AD) severity is essential for therapeutic decision making and monitoring treatment progress. However, there are a myriad of clinical measurement tools available, some of which are impractical for routine clinical use despite being recommended for clinical trials in AD. For measurement tools to be used in clinical practice, they should be valid, reliable, rapidly completed, and scored, and easily incorporated into existing clinic workflows. This narrative review addresses content, validity, and feasibility, and provides a simplified repertoire of assessments for clinical assessment of AD based on prior evidence and expert opinion. Tools that may be feasible for clinical practice include patient-reported outcomes (eg, dermatology life quality index, patient-oriented eczema measure, numerical rating scales for itch, pain, and sleep disturbance, AD Control Tool, and patient-reported global assessment), and clinician-reported outcomes (eg, body surface area and investigator's global assessment). AD is associated with variable clinical signs, symptoms, extent of lesions, longitudinal course, comorbidities, and impacts. Any single domain is insufficient to holistically characterize AD severity, select therapy, or monitor treatment response. A combination of these tools is recommended to balance completeness and feasibility.","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":null,"pages":null},"PeriodicalIF":5.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9273816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Diagnostic Value of Delayed-Type Reactions to Perennial Aeroallergens for Atopic Disease. 对多年生空气过敏原的延迟型反应对特应性疾病的诊断价值。

IF 5.2 3区医学

Dermatitis Pub Date : 2024-01-01 Epub Date: 2023-05-03 DOI: 10.1089/derm.2022.0050

Puneet Arora, Rebecca L Freese, Paul L Bigliardi

{"title":"The Diagnostic Value of Delayed-Type Reactions to Perennial Aeroallergens for Atopic Disease.","authors":"Puneet Arora, Rebecca L Freese, Paul L Bigliardi","doi":"10.1089/derm.2022.0050","DOIUrl":"10.1089/derm.2022.0050","url":null,"abstract":"Background: Delayed-type reactions to aeroallergens have been observed, however, their clinical significance continues to be debated. Objective: We assessed the prevalence and significance of delayed-type reactions to aeroallergens in atopic patients. Methods: Retrospective study including 266 patients with history or evidence of atopic disease (atopic dermatitis [AD], allergic rhinitis, and/or allergic asthma) and tested via either the intradermal skin test (IDT) or atopy patch test for common aeroallergens, specifically house dust mites (Dermatophagoides farinae, Dermatophagoides pteronyssinus) and perennial molds (Aspergillus fumigatus, Penicillium notatum). All patients were tested via IDT with both immediate (15 minute) and delayed (2 and 4 days) readings. Delayed reading was considered positive if the IDT injection site demonstrated at least 5 mm induration 48 hours after inoculation. Results: In total, 195 (73.3%) patients demonstrated an immediate-type reaction, whereas 118 (44.4%) had a delayed-type reaction. In total, 75 (28.2%) patients experienced both immediate- and delayed-type reactions, 43 (16.2%) reacted delayed-type only, and 85.3% of delayed-type reactions to individual aeroallergens were associated with eczematous lesions predominantly in air-exposed areas. Conclusion: Delayed-type reactions to aeroallergens are prevalent and clinically significant as a component of extrinsic AD and atopic diseases. The data support delayed reading of the IDT to guide diagnosis and management in these patients.","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":null,"pages":null},"PeriodicalIF":5.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10913491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9460838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IgE-Mediated Hypersensitivity Reaction to Carboxymethyl Cellulose in an Injectable Cosmetic Filler. 注射美容填充剂中的羧甲基纤维素引发的 IgE 媒介超敏反应。

IF 5.2 3区医学

Dermatitis Pub Date : 2024-01-01 Epub Date: 2023-05-02 DOI: 10.1089/derm.2023.0015

Helena Pires Pereira, Joni Costa Carvalho, Rafael Santiago, Inês Neves, Carlos Loureiro, Ana Todo-Bom

引用次数: 0

Eosinophilic Dermatitis due to Triptorelin Pamoate in a Patient with Prostate Cancer Confirmed by Patch Testing. 经斑贴试验证实的前列腺癌患者帕莫酸曲普瑞林引起的嗜酸性皮炎

IF 5.2 3区医学

Dermatitis Pub Date : 2024-01-01 Epub Date: 2023-07-11 DOI: 10.1089/derm.2023.0024

Dimitra Koumaki, Stamatios Gregoriou, Leonidas Marinos, Alexander Katoulis, Marios Papadakis, Georgios Evangelou, Konstantinos Krasagakis

引用次数: 0